Australia markets closed

Merck KGaA (0O14.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
152.00-2.50 (-1.62%)
At close: 06:08PM BST

Merck KGaA

Frankfurter Strasse 250
Darmstadt 64293
49 6151 72 0

IndustryDrug Manufacturers - Specialty & Generic
Full-time employees63,712

Key executives

NameTitlePayExercisedYear born
Ms. Belen Garijo Lopez M.D.Chair of Exec. Board & CEO5.9MN/A1960
Ms. Helene von RoederCFO & Member of Exec. Board80kN/A1970
Dr. Kai BeckmannCEO of Electronics & Member of the Exec. Board4.51MN/A1965
Mr. Peter GuenterCEO of Healthcare Bus. & Member of Exec. Board5.2MN/A1962
Dr. Matthias J. HeinzelCEO of Life Science Sector & Member of Exec. Board4.06MN/A1967
Mr. Constantin FestHead of Investor RelationsN/AN/A1977
Dr. Friederike RotschGroup Gen. Counsel and Head of Group Legal & ComplianceN/AN/A1972
Ms. Barbara WeilandChief Compliance OfficerN/AN/A1974
Mr. Dietmar EidensHead of the Global HR Bus. Partner OrganizationN/AN/A1958
Mr. Frank GotthardtHead of Corp. & Gov. Relations - EuropeN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Merck KGaA operates as a science and technology company in Germany. The company's Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company's Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Corporate governance

Merck KGaA’s ISS governance QualityScore as of 1 October 2023 is 7. The pillar scores are Audit: 3; Board: 8; Shareholder rights: 10; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.